Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis

Background: The non-steroidal mineralocorticoid receptor antagonists (MRAs) are promising treatments in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We conducted a meta-analysis to explore the efficacy and safety of the non-steroidal MRAs (finerenone, apararenone, esaxerenon...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Xinrui Jiang, Zhengji Zhang, Chunlu Li, Shijin Zhang, Qiang Su, Siyun Yang, Xin Liu, Ying Hu, Xiaofeng Pu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Subjects:	finerenone apararenone esaxerenone mineralocorticoid receptor antagonists type 2 diabetes chronic kidney disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.896947/full

Similar Items

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
by: Akira Sezai, et al.
Published: (2025-05-01)

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
by: Jinfei Wu, et al.
Published: (2025-09-01)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
by: Lan Yao, et al.
Published: (2023-12-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

A Trial of Finerenone in a Patient with Primary Aldosteronism
by: Sandra Karanović Štambuk
Published: (2024-09-01)

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
by: Julia J. Liang, et al.
Published: (2025-03-01)

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
by: Richard EL, et al.
Published: (2025-04-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
by: Francesco Piccirillo, et al.
Published: (2023-05-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
by: Hongxuan Fan, et al.
Published: (2025-08-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
by: Mai Rosenberg, et al.
Published: (2024-09-01)

Assessment of renal and cardiovascular risks in patients with type 2 diabetes when using non-steroidal mineralocorticoid receptor antagonists
by: V.М. Yerokhovych, et al.
Published: (2023-12-01)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
by: Kazuomi Kario, et al.
Published: (2023-09-01)

Effect of esaxerenone on the onset of aortic endothelial dysfunction and circulating microparticles in type 1 diabetic male mice
by: Kumiko Taguchi, et al.
Published: (2024-11-01)

Antihypertensive effect of esaxerenone and correlation between brachial and wrist home monitoring devices in patients with nocturnal hypertension: A post hoc analysis of the EARLY‐NH study
by: Kazuomi Kario, et al.
Published: (2024-07-01)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
by: Ruolin Lv, et al.
Published: (2023-02-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Blocking mineralocorticoid signaling with esaxerenone reduces atherosclerosis in hyperglycemic ApoE KO mice without affecting blood pressure and glycolipid metabolism
by: Hideyuki Iwamoto, et al.
Published: (2025-03-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
by: Arga Setyo Adji, et al.
Published: (2024-11-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
by: Ixchel Lima Posada, et al.
Published: (2024-06-01)

Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
by: Mohamad El Wardani, et al.
Published: (2023-03-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01)

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
by: Deep Dutta, et al.
Published: (2022-01-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)